Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.30 |
| ▸ | HTR3B | O95264 | 1/20 | 0.30 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.30 |
| ▸ | HTR3A | P46098 | 1/20 | 0.30 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.30 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10656286 | 0.62 | LMNA (0.35) | LMNASIGMAR1MEN1NPC1RAB9A | |
| SCHEMBL3860610 | 0.61 | LMNA (0.39) | LMNASIGMAR1MEN1NPC1RAB9A | |
| SCHEMBL1406399 | 0.61 | — | — | |
| SCHEMBL7113548 | 0.61 | POLB (0.35) | LMNASIGMAR1MEN1NPC1RAB9A | |
| SCHEMBL3412417 | 0.59 | LMNA (0.41) | LMNASIGMAR1MEN1NPC1RAB9A | |
| SCHEMBL10582068 | 0.59 | LMNA (0.46) | LMNASIGMAR1MEN1NPC1RAB9A | |
| SCHEMBL3860609 | 0.58 | SIGMAR1 (0.40) | LMNASIGMAR1MEN1NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL5446411 | 0.57 | LMNA (0.39) | LMNASIGMAR1MEN1NPC1RAB9A | |
| SCHEMBL11318307 | 0.56 | LMNA (0.39) | LMNASIGMAR1MEN1NPC1RAB9A | |
| SCHEMBL7113551 | 0.56 | LMNA (0.34) | LMNASIGMAR1MEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439242-B2 | PPARγ modulators | AMGEN INC. (US) | 2008-10-21 | — | — | US | disclosed |
| CN-1171872-C | Compounds that modulate PPAR γ activity | �㽭�пؼ����ɷ�����˾ | 2004-10-20 | — | — | CN | disclosed |
| US-6620827-B2 | Peroxisome proliferator-activated receptors-gamma to control lipid metabolism ane obesity; antidiabetic, -inflammatory and -arthritic agents; non-insulin dependent diabetes; antilipemic and -cholesterol agents | TULARIK INC. | 2003-09-16 | — | — | US | disclosed |
| CN-1368961-A | Compounds that modulate PPAR γ activity | TULARIK INC (US) | 2002-09-11 | — | — | CN | disclosed |
| EP-1192137-A1 | COMPOUNDS FOR THE MODULATION OF PPAR$g(g) ACTIVITY | Tularik Inc. (US) | 2002-04-03 | — | — | EP | disclosed |
| US-20010027200-A1 | PPARgamma modulators | TULARIK INC. | 2001-10-04 | — | — | US | disclosed |
| US-6200995-B1 | PYRIDYLOXYBENZENESULFONAMIDE DERIVATIVES; DIABETES, OBESITY | TULARIK INC. | 2001-03-13 | — | — | US | disclosed |
| WO-2001000579-A1 | COMPOUNDS FOR THE MODULATION OF PPARη ACTIVITY | TULARIK INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| EP-1053227-A1 | PPAR-GAMMA MODULATORS | TULARIK, INC. (US) | 2000-11-22 | — | — | EP | disclosed |
| WO-1999038845-A1 | PPAR-GAMMA MODULATORS | TULARIK INC. (US) | 1999-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010027200-A1 | PPARgamma modulators | PPARG, PPARA, PPARD | LMNA 2066/4885SIGMAR1 1880/4885MEN1 4878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.